Cyclacel Pharmaceuticals, Inc. (CYCC) Posts Q1 Loss of 25c/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. TMUS
9. VZ
10. LMT

Go back to Cyclacel Pharmaceuticals, Inc. (CYCC) Posts Q1 Loss of 25c/Share

Cyclacel Pharmaceuticals Reports First Quarter 2014 Financial Results

May 13, 2014 4:05 PM EDT

BERKELEY HEIGHTS, N.J., May 13, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the first quarter ended March 31, 2014.

The Company's net loss applicable to common shareholders for the first quarter ended March 31, 2014 was $4.9 million, or $0.25 per basic and diluted share, compared to a net loss applicable to common... More